Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.
OBJECTIVE
To determine the kinetics of the formation of 6beta-naltrexol from naltrexone in human liver cytosol, and to investigate the role of potential inhibitors.


METHODS
The kinetics of the formation of 6 beta-naltrexol from naltrexone were examined in eight human liver cytosol preparations using h.p.l.c. to quantify 6 beta-naltrexol and, the extent of inhibition of 6 beta-naltrexol formation was determined using chemical inhibitors. The formation of 6 beta-naltrexol and the back reaction of 6 beta-naltrexol to naltrexone were also examined in a microsomal preparation.


RESULTS
The Vmax, Km and CLint values for the formation of 6 beta-naltrexol from naltrexone were in the ranges of 16-45 nmol mg-1 protein h-1, 17-53 microM and 0.3-2.2 ml h-1 mg-1 protein, respectively. The steroid hormones testosterone (Ki = 0.3 +/- 0.1 microM) and dihydrotestosterone (Ki = 0.7 +/- 0.4 microM) were the most potent competitive inhibitors of 6 beta-naltrexol formation, with naloxone, menadione and corticosterone also producing > 50% inhibition at a concentration of 100 microM. The opioid agonists morphine, oxycodone, oxymorphone and hydromorphone, and a range of benzodiazepines showed < 20% inhibition at 100 microM. In the microsomal preparation, there was no formation of naltrexone from 6beta-naltrexol nor any formation of 6beta-naltrexol from naltrexone.


CONCLUSIONS
The intersubject variability in the kinetic parameters of 6beta-naltrexol formation could play a role in the efficacy of and patient compliance with naltrexone treatment. This variability could be due in part to a genetic polymorphism of the dihydrodiol dehydrogenase DD4, one of the enzymes reported to be responsible for the formation of 6beta-naltrexol from naltrexone. DD4 also has hydroxysteroid dehydrogenase activity which could account for the potent inhibition by the steroid hormones testosterone and dihydrotestosterone. The clinical significance of the latter finding remains to be established.
Porter
S J
SJ
Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia. susan.porter@adelaide.edu.au
Somogyi
A A
AA
White
J M
JM
D000328:Adult; D000368:Aged; D000701:Analgesics, Opioid / Q000494:pharmacology; D001569:Benzodiazepines / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D003345:Corticosterone / Q000494:pharmacology; D003600:Cytosol / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D013196:Dihydrotestosterone / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000493:pharmacokinetics; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D010098:Oxycodone; D015203:Reproducibility of Results; D013379:Substrate Specificity; D013739:Testosterone / Q000494:pharmacology; D014812:Vitamin K / Q000494:pharmacology
D000701:Analgesics, Opioid; D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D014812:Vitamin K; D001569:Benzodiazepines; D009270:Naloxone; D013739:Testosterone; C010410:6 beta-hydroxynaltrexone; D009271:Naltrexone; D010098:Oxycodone; D010088:Oxidoreductases; D003345:Corticosterone